Business, energy, technology, markets and global industry news from Business News Today

PTEN-deficient prostate cancer

PharmaDeviceNews PTEN-deficient prostate cancer
Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.
Medical Devices & Diagnostics

Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer

Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.

Read More
Representative image: AstraZeneca’s TRUQAP prostate cancer push highlights the growing role of targeted therapy and PTEN testing in metastatic hormone-sensitive prostate cancer treatment.
Pharma & Biotech

Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment

TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.

Read More